DOMAIN Therapeutics

The countdown begins! 🌟 We’re thrilled to be running for the prestigious Prix Galien USA Award in the “Best Startup” category. With just under two weeks to go until the grand reveal on the November 7th and our excitement is building. At Domain, our groundbreaking #innovation continues to push the boundaries of science and medicine. With over two decades of GPCR expertise, we’re developing revolutionary immunotherapies that target GPCR-mediated immunosuppression. Our unique precision-based approach leverages the power of immunity, aiming to overcome the limitations of existing treatments and deliver more effective therapeutic solutions for patients with high unmet needs. Our journey wouldn’t be possible without the dedication of our incredible team and the unwavering support of our visionary international venture capital partners. Their commitment and collaboration have enabled us to build a differentiated and diverse portfolio of best-in-class and first-in-class assets, addressing several immunosuppressive mechanisms and immunoresistance within the tumor microenvironment. Our unique understanding of the role of GPCRs in modulating the immune system is foundational to this work. Validated through multiple pharma partnerships across various therapeutic areas, our robust pipeline of GPCR-targeting drug candidates has shown promising results in preclinical and clinical trials. The future of GPCR #drugdiscovery is bright and our expertise in novel modalities with improved GPCR selectivity keeps us at the forefront of pioneering unique therapeutic strategies. We want to thank The Galien Foundation and Business France North America for this nomination and recognition. We look forward to connecting with leading innovators and fellow nominees who are driving breakthrough advancements in clinical research across the #lifesciences industry. The Prix Galien Awards ceremony will be an incredible opportunity to celebrate progress in our industry and explore new horizons together. Stay tuned and keep your fingers crossed for us! 🚀   3B Future Health Fund I & II, Seventure Partners, Schroders Capital, Omnes, Turenne Groupe, Theodorus Investment Funds, Panacea Venture, Viva BioInnovator, CTI Life Sciences Fund, adMare BioInnovations #HealthInnovation #immunooncology #CancerResearch #drugdevelopment 

In the fiercely competitive world of #cancer therapeutics, the challenge is clear: How can we overcome immunoresistance and deliver truly effective treatments for non-responding cancer patients? While immune-checkpoint inhibitors have revolutionized treatment, tumor-infiltrating Tregs suppress the immune response, leading to resistance and compromising the efficacy of these treatments. The need for innovation is urgent, and the opportunity is immense! Join Stephan Schann, our Chief Scientific Officer, for a highly informative presentation at the 17th #DrugDiscovery Strategic Summit: 📍Location: Leonardo Hotel Munich Arabellapark, Munich, Germany 🗓 Date: October 23rd l 1:25-1:50 pm CET Stephan will unveil our groundbreaking anti-CCR8 candidate, DT-7012, a best-in-class monoclonal antibody that depletes tumor-infiltrating Tregs through advanced ADCC/ADCP mechanisms. DT-7012 effectively transforms the tumor microenvironment into an immunocompetent one, empowering the immune system to drive tumor regression. At Domain, we accelerate #innovation by leveraging our pioneering precision-based science, rooted in a unique understanding of GPCRs and their pivotal role in the immune system modulation. Achieving a remarkable 100% complete response rate in preclinical monotherapy, DT-7012 showcases breakthrough therapeutic properties complemented by a robust biomarker strategy. This targets the immunosuppressive environment created by Tregs, which often undermines the effectiveness of traditional therapies. DT-7012 is positioned for clinical success, unlock the immune system's cancer-fighting abilities and creating significant market impact. This program offers a powerful new therapeutic solution to address unmet medical needs. The upcoming summit is an incredible opportunity to connect with industry leaders and decision-makers. Let's discuss how Domain Therapeutics can drive transformative advancements in #immunooncology and transform your drug discovery pipeline. Don't miss out! We look forward to seeing you in Munich later this week. Let's explore how, together, we can drive GPCR science forward and pave the way for innovative approaches to make a meaningful impact in the lives of cancer patients worldwide. #networking #immunotherapy #drugdevelopment Agile Falcon Strategic Group LLC.

Last week, we were thrilled to join the 2nd Symposium on Microenvironment and #Immunotherapy of Sarcomas, hosted by RHU CONDOR, which took place last week in Bordeaux, France. This symposium is a vital platform for advancing our understanding of soft tissue sarcomas (STS) and exploring innovative treatment strategies that address specific challenges faced by patients. Why is this important? STS are rare and often diagnosed late. Despite well-conducted surgeries, up to 40% of patients develop metastatic relapse, with standard treatments offering limited effectiveness. But there’s hope! The RHU CONDOR, led by Prof. Italiano Antoine, an esteemed member of Domain's Scientific Advisory Board (SAB), aims to revolutionize treatment options for STS patients by combining #precisionmedicine and immunotherapies. As proud members of this groundbreaking program, we're dedicated to pioneering innovations in GPCR-targeting immunotherapies. Our lead clinical candidate, DT-9081, an EP4R antagonist, is set to enter Phase II in early 2025. DT-9081 has the potential to improve immune responses to sarcoma and address resistance mechanisms to current therapies, offering greater benefits to patients. We had the pleasure of attending insightful presentations by Florent Petitprez The University of Edinburgh Prof. Wolf Hervé Fridman Université Paris Cité Dr. Sandra D'Angelo Memorial Sloan Kettering Cancer Center Dr. Ryan Denu MD Anderson Cancer Center. Additionally, Prof. John Stagg, another distinguished member of Domain's SAB, discussed targeting GPCRs in solid tumors, highlighting the role of PAR2 in cancer immunity. Dr. Thibaut Brugat, our Head of Portfolio, also gave an engaging presentation on therapeutic target identification and selection of a drug candidate with a superior mode of action. Together, we're paving the way for more effective and safer treatments for sarcoma patients. Stay tuned for more updates on our journey to innovate and drive meaningful change for those affected by this challenging disease! #Healthinnovation #cancerresearch #drugdevelopment

October is here, and with it comes Pink October, a global movement that unites individuals, communities and organizations to raise awareness about breast #cancer and make a difference. This month, we at Domain Therapeutics are proud to stand with millions around the world in this important fight. With smiles and determination, our dedicated Team joined over 12K participants in the 15th edition of La Strasbourgeoise breast cancer awareness event. Whether running the 5 km race or joining the walk, the experience was incredible. It reminded us that every gesture counts in this vital cause. The atmosphere was vibrant, and we gave our best as one team! Breast cancer is one of the most common cancers worldwide, affecting countless lives. It’s a battle we fight together. Just as early detection is crucial for improving recovery chances in some cases of cancer, #innovation is essential to develop more effective and safer treatments for patients. At Domain, we’re deeply committed to this cause. #Immunotherapy treatments work by stimulating the immune system’s natural ability to fight cancer. However, some tumors can deploy different immunosuppressive strategies to escape immunosurveillance leading to treatment relapse. This is why our innovative work focuses on understanding the complexities of tumors and their immunosuppressive mechanisms. By doing so, we aim to overcome the limitations of current treatments and optimize patient outcomes in the clinic. Together, we can make a difference! This October and beyond, let’s think pink, support research and say no to breast cancer or any other types of cancer! 💗 Congratulations to all the participants and see you next year! ✊✊✊ #drugdevelopment #Healthinnovation #cancerresearch

Will you be at the Society for Neuroscience annual meeting in Chicago? Join Guilhem Dugast, expert from our subsidiary in North America, for a presentation of their groundbreaking work in #collaboration with Mindstate Design Labs. We're thrilled to showcase the power of our bioSens-All® platform, a breakthrough biosensor technology, in advancing #GPCR profiling, specifically focusing on the 5-HT7a serotonergic receptor. 🧠 Poster presentation details 🧠 💡 Title: "Comprehensive pharmacological profiling of the human 5-HT7a receptor isoform exposes novel signaling." 📅 When: Sunday, October 6th, between 3 and 4 pm CDT 📍 Where: Poster board PSTR143.11 For over two decades, Domain Therapeutics has been at the forefront of GPCR #drugdiscovery, transforming therapeutic target identification to deliver more effective solutions for patients. Our bioSens-All® technology has been instrumental in enabling a thorough analysis of complex GPCR signaling pathways with unmatched precision, opening up new therapeutic opportunities through collaborations with innovative biotechs as well as pharma industry leaders. This exciting project with Mindstate Design Labs, reveals novel insights that could pave the way for new therapies for neurological and psychiatric conditions, including anxiety, depression, schizophrenia, and Alzheimer’s disease. We're eager to engage with brilliant researchers in Chicago, share our latest findings and demonstrate how we are shaping the future of GPCR-targeting therapies through innovative collaborations! Come meet our team and learn more about our exciting work! #neuroscience #healthinnovation #biotechnology

🔍Is C-C chemokine receptor type 8 (CCR8) the next big breakthrough in cancer #immunotherapy?  CCR8, a GPCR family receptor, has emerged as a ‘hot’ target in #cancertreatment. But why is it so intriguing? Targeting CCR8 presents challenges due to its pharmacological complexity, requiring deep expertise and novel insights to unveil its sophisticated nature. At Domain, we’re at the forefront of this exciting development, pioneering a precision-driven approach to CCR8 targeting. Our breakthrough candidate, DT-7012, a best-in-class Treg-depleting ADCC/ADCP anti-CCR8 monoclonal antibody, stands out due to its competitive properties. DT-7012 demonstrates unmatched precision in targeting CCR8, selectively depleting tumor-resistant Tregs and transforming the immunocompromised tumor microenvironment into an immunocompetent one. This amplifies the anti-tumor response, fostering tumor regression and promoting the activity of effector T cells within tumors. DT-7012 shows exceptional potential to overcome resistance to immunotherapy, thereby increasing clinical success rate of treatments. Notably, it benefits non-responding patients with cancer, including patients with PD-1 resistant tumors. A big thank you to Jacob Plieth for including DT-7012 into your article on OncologyPipeline, highlighting a surge in clinical activity around CCR8 by the leading pharmaceutical companies, further validating its potential as a game-changing target. As the competitive landscape is heating up, DT-7012 joins the race among other preclinical anti-CCR8 mAbs. Precision science and #innovation drive us forward 🚀 DT-7012 is currently in the pre-IND stage. Our comprehensive translational research strategy, fueled by an in-depth understanding of CCR8 pharmacology and precise biomarker analysis, aims to inform the first-in-human clinical study design for DT-7012, de-risking and increasing its efficiency. If you’re as excited as we’re about CCR8, hit that “Like” button and spread the word 🙌  Let’s rewrite the future of cancer treatment together! #immunooncology #CancerResearch #drugdevelopment #biotechnology

We are just days away from the 22nd annual Discovery on Target event in Boston, where our CSO, Dr. Stephan Schann, will be sharing our latest advancements in GPCR-targeting immunotherapies, addressing the critical challenge of #immunotherapy resistance in #cancer treatment. At Domain Therapeutics, precision is our guiding principle. We're committed to overcoming the limitations of current treatment methods and bringing innovative solutions to patients experiencing therapeutic failure in the clinic. Our expertise in GPCRs, pivotal receptors involved in numerous diseases, is widely recognized and is paving the way for new therapeutic possibilities in cancer. 📅 Event highlight: Join Dr. Stephan Schann at the "Small Molecules for Cancer Targets" conference on October 2nd at 9:00 am. He will be discussing "GPCRs of the Tumor Microenvironment as Novel #Immunooncology Drug Targets". 🔬Presentation highlights: ▪ DT-9081 (best-in-class EP4R antagonist): Currently in Phase I trial, this immunotherapy targets prostaglandin E2 (PGE2)-mediated resistance restoring immune system functionality to fight tumors more effectively. DT-9081 could lead to more sustainable and potent treatments for cancer patients. ▪ DT-9045 (first-in-class PAR2 Negative Allosteric Modulator): A game-changer in immuno-oncology, targeting several immune effectors, including cancer-associated fibroblasts (CAF) that contribute to tumor growth. Its unique therapeutic potential opens solid perspectives for treating tumors with high unmet needs. Our goal is to develop treatments that are not only innovative but also fundamentally transformative for patients worldwide. We look forward to connecting with fellow innovators and thought leaders at the event! 🌐 Curious to learn more? Connect with Dr. Stephan Schann at the event or visit our program pages via the link in comments to explore our groundbreaking therapies. Let's drive #HealthInnovation together! Cambridge Healthtech Institute #cancerresearch #drugdevelopment

At Domain Therapeutics, sustainability isn't just an initiative—it’s deeply embedded in how we approach our mission as a #biopharma company. As we develop innovative therapies to improve lives, we're equally committed to reducing our environmental footprint and driving positive change. With #WorldCleanUpDay just around the corner, we're excited to share the steps we've taken recently, as part of our ambitious eco-friendly policy, to minimize waste and ensure responsible recycling practices: 🔬 Lab Clean-Up: We've given new life to lab benches, consumables and equipment by donating them to local faculties Institut de Physique et de Chimie des Matériaux de Strasbourg - IPCMS ECPM Ecole européenne de chimie polymères et matériaux de Strasbourg. This not only reduces lab waste but also gives unused equipment a second life, supporting education. ♻️ Recycle & Repurpose: From donating furniture to associations and employees to selling equipment with a help of anti-waste experts Labsquare, we're making sure nothing goes to waste. 🔄 Partnering with Sustainable Companies: Collaborating with R'SEEDS for waste sorting during lab renovations and Rosachem for recycling of unused equipment, we're making #sustainability a team effort. 💻 IT Sustainability: By extending the life of our PCs beyond 5 years through repairs, thanks to our IT policy, we are reducing e-waste. These actions are part of our broader vision to foster a culture of sustainability that empowers future generations and drives responsible #innovation. Every small act adds up to a monumental change! A special thanks to our partners for helping us keeping our waste to an absolute minimum. Together, we can create a cleaner, healthier, waste-free future for our planet 🌳 Let's make a difference! #drugdevelopment #immunotherapy Let's Do It World Official World Cleanup Day Official

How targeting EP4 receptor can transform #immunotherapy and improve patient outcomes? EP4 antagonists, which inhibit the EP4 receptor, represent a captivating frontier in #immunooncology. A deeper understanding of their potential applications could lead to significant advancements in #cancertreatment. The EP4 receptor is the G protein coupled receptor (GPCR) that, upon binding with its natural Prostaglandin E2 (PGE2), can trigger immune cell modulation, suppressing the immune response and promoting cancer cell survival and proliferation. While COX-2 inhibitors, which aim to inhibit the COX-2 enzyme responsible for PGE2 production, have shown promise in addressing immunosuppression, their development has been hindered by safety concerns. New approaches are needed, and research published in Nature by Jan Böttcher and George Coukos has linked PGE2 released by tumor cells to the inhibition of tumor-infiltrating lymphocytes (TILs) by modulating IL-2 signaling. Additionally, Julian Downward’s research in AACR Journals highlights that KRAS promotes COX-2 expression leading to PGE2 secretion. Yet, the resistance to KRAS targeting therapies is associated with PGE2 revival, risking tumor relapse. These findings underscore the potential risk of triggering PGE2-mediated immunosuppression in patients undergoing TIL-ACT and KRAS therapies. At Domain, we are unlocking the full therapeutic potential of GPCRs to deliver game-changing therapies. By effectively blocking EP4 receptor, our lead clinical candidate, DT-9081, has the potential to be best-in-class in dampening immunosuppressive cells while simultaneously boosting the activity of immunocompetent cells, offering an improved safety profile compared to current treatments. With a strong biomarker plan in place, we believe that DT-9081 holds promise in increasing the efficacy of cancer immunotherapies and extending the range of innovative treatments available to cancer patients. Let’s work together to bring new hope to patients worldwide! 🌍💡 #CancerResearch #drugdevelopment #biotechnology

🚀We’re beyond excited to share that our company has been nominated for the prestigious Prix Galien USA in the “Best Startup” category!🏆 This incredible honor reflects our unwavering commitment to #innovation and excellence in developing groundbreaking treatments that target GPCR-mediated immunosuppression, aiming to overcome the limitations of current therapies. At Domain, we are at the forefront of two transformative fields: G Protein-Coupled Receptors (GPCRs) and the immune system. GPCRs are pivotal in #drugdiscovery, accounting for 30% of all marketed drugs, yet their full potential remains untapped. The intricacies of immunosuppression and immunoresistance within the Tumor Micro-Environment significantly impact treatment outcomes, often leading to therapeutic failure for some cancer patients. By integrating GPCRs and immune system, we are pioneering a new frontier in #immunooncology, redefining therapeutic possibilities for cancer patients with high unmet needs. This synergy, still largely unexplored, holds immense promise, offering vast opportunities for #drugdevelopment in #cancertreatment. Leveraging our cutting-edge target (GPCR) identification platform and precision science that builds upon two decades of GPCR expertise, we deliver a unique pipeline of GPCR-targeting drug candidates with competitive properties. We’re deeply honored to be recognized by The Galien Foundation and Business France North America. 🗓️Mark your calendars for the Prix Galien USA Forum on the 7th of November, where winners will be announced! Our journey is powered by visionary international venture capital firms, including 3B Future Health Fund I & II, Seventure Partners, Schroders Capital, Omnes, Turenne Groupe, Theodorus Investment Funds, Panacea Venture, Viva BioInnovator, CTI Life Sciences Fund and adMare BioInnovations. Their belief in our mission drives us forward, and we are immensely grateful for their support. Together, we’re revolutionizing precision-enabled immunotherapies, making them accessible to patients worldwide! 🌍✨